FDA Approves BUPRENORPHINE AND NALOXONE — Actavis Pharma, Inc.

Actavis Pharma, Inc. has secured FDA approval for its **buprenorphine and naloxone** (generic) tablets/sublingual film, expanding the availability of this long-acting opioid agonist therapy despite limited competition. The approval is expected to alleviate potential market shortages of this combination product, providing providers with critical alternatives for medication-assisted treatment of opioid dependence.